Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Kailera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026.
- Filed
- May 26, 2026, 4:29 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-239417
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $70,873 | $10,130 |
| General and administrative | 13,787 | 10,328 |
| Total operating expenses | 84,660 | 20,458 |
| Loss from operations | (84,660) | (20,458) |
| Other income | ||
| Interest income | 5,716 | 1,675 |
| Other income, net | 79 | 800 |
Item 1. Financial Statements.
FAQ
- What is Kailera Therapeutics's R&D?
- Kailera Therapeutics (KLRA) reported R&D of $70.87M in Q1 2026.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Kailera Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude